FDA warned Online Generic Medicine that its website sells unapproved, misbranded injectable semaglutide to U.S. consumers.
What happened
FDA reviewed www.onlinegenericmedicine.com on August 26, 2026, and September 2, 2026. FDA found the website offered "Semanat Injection (Semaglutide)," an injectable semaglutide product with no FDA-approved application. FDA also found the product was offered without requiring a prescription and its labeling lacked adequate directions for use.
What FDA found
The company offered an unapproved new drug without an FDA-approved application.
Sections 301(d) and 505(a) of the FD&C Act (21 U.S.C. 331(d) and 355(a))The drug's labeling did not include adequate directions for use by a layperson.
Section 502(f)(1) of the FD&C Act (21 U.S.C. 352(f)(1))The company offered a prescription drug without requiring a prescription.
Sections 503(b)(1) and 301(k) of the FD&C Act (21 U.S.C. 353(b)(1) and 331(k))
What FDA wants
FDA tells the company to stop offering any unapproved and misbranded drugs for sale to U.S. consumers. The company must send a written response within 15 business days of receipt, including corrective steps and documentation, citing reference number MARCS-CMS 737806.
Who should pay attention
- online pharmacies selling prescription drugs
- telehealth and weight-loss companies promoting GLP-1 products
- consumers buying semaglutide online
This is a summary. Read the original letter on fda.gov.